Gambardella, Valentina
Lombardi, Pasquale
Carbonell-Asins, Juan Antonio
Tarazona, Noelia
Cejalvo, Juan Miguel
González-Barrallo, Inés
Martín-Arana, Jorge
Tébar-Martínez, Roberto http://orcid.org/0000-0001-8263-0513
Viala, Alba
Bruixola, Gema
Hernando, Cristina
Blasco, Inma
Papaccio, Federica
Martínez-Ciarpaglini, Carolina
Alfaro-Cervelló, Clara
Seda-García, Enrique
Blesa, Sebastián
Chirivella, Isabel
Castillo, Josefa
Montón-Bueno, José Vicente
Roselló, Susana
Huerta, Marisol
Pérez-Fidalgo, Alejandro
Martín-Martorell, Paloma
Insa-Mollá, Amelia
Fleitas, Tania
Rentero-Garrido, Pilar
Zúñiga-Trejos, Sheila
Cervantes, Andrés http://orcid.org/0000-0003-3806-3691
Roda, Desamparados
Article History
Received: 4 April 2021
Revised: 14 May 2021
Accepted: 16 July 2021
First Online: 7 September 2021
Ethics approval and consent for publication
: The study was approved by the institutional Ethics Committee of the Hospital Clínico Universitario de Valencia. This study included patients with advanced solid tumours, who were referred to our Early-Phase Trials Unit at the Hospital Clínico of Valencia, Spain, as potential candidates to be enrolled in early clinical trials from January 2019 to April 2020. All patients signed an informed consent form for the molecular analysis and the specific consent to be enrolled into each clinical trial. The study was conducted in accordance with the Declaration of Helsinki, and was approved by the institutional review board. Written informed consent was obtained from all patients to perform the molecular analysis. The datasets, including the redacted study protocol, redacted statistical analysis plan and individual participant’s data supporting the results reported in this article, will be made from the corresponding author on reasonable request.
: AC declares institutional research funding from Genentech, Merck Serono, BMS, MSD, Roche, Beigene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas, Takeda, Natera and Fibrogen and advisory board or speaker fees from Angem, Merck Serono, Roche, Bayer, Servier and Pierre Fabre in the past 5 years. All remaining authors declare no competing interests.